Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xanodyne Pharmaceuticals Inc.

www.xanodyne.com

Latest From Xanodyne Pharmaceuticals Inc.

Public Citizen Asks US FDA To Ban Olmesartan Hypertension Medicines

Given risk of serious gastrointestinal disorder, Public Citizen argues there is no reason to keep the drugs on the market when so many alternative treatments are available

.

BioPharmaceutical Regulation

FDA Forced To Update Approved Products List In Do-Not-Compound Review

ANDAs mistakenly still are cataloged as approved even though they have been withdrawn from marketing.

BioPharmaceutical United States

Generic Relabeling Speed Could Get Supreme Court Review

Supreme Court asks the Solicitor General to weigh in on whether a state tort claim that Teva did not immediately update its generic Fosamax labeling is preempted by federal law; thousands of such suits have arisen in wake of high court’s Mensing decision.

BioPharmaceutical United States

Depomed Eyes More Acquisitions With PDL Royalty Sale Cash

The specialty pharma plans additional purchases that fit into its growing pain and neurology portfolio, after a late-stage failure in women’s health. With the cash infusion, it may make bigger deals than before.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Xanodyne Pharmacal Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Xanodyne Pharmaceuticals Inc.
  • Senior Management
  • Natasha Giordano, Pres. & CEO
    Rita M O'Connor, Chief Financial & Information Officer
  • Contact Info
  • Xanodyne Pharmaceuticals Inc.
    Phone: (859) 371-6383
    1 Riverfront Pl.
    Newport, KY 41071
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register